At Orchard, we’re committed to working closely with physicians and others in the healthcare community to advance research into ex vivo autologous gene therapy and improve outcomes for people affected by rare inherited diseases.
Healthcare providers requesting information on Orchard’s approved or pipeline programs may contact firstname.lastname@example.org or (UK) +44 800 098 8438.
Strimvelis® is a gammaretroviral vector-based gene therapy approved by the European Medicines Agency in 2016. It was the first ex vivo autologous gene therapy approved by the EMA. Strimvelis® has not been approved by the FDA.
For more information about Strimvelis®, visit the EMA website.
To report an adverse event or side effect, contact us at OrchardPostPVG.SM@ppdi.com or (UK) +44 20 3973 5805. For all other medical inquiries, healthcare providers may contact email@example.com or (UK) +44 800 098 8438.
Independent Medical Education
Orchard supports independent medical education on our therapeutic areas of interest and on emerging developments in gene therapy. For more information and to apply, please contact firstname.lastname@example.org.
Orchard supports investigator-initiated research on the diagnosis, natural history and other topics relevant to our indications. For more information and to apply, please contact email@example.com.
Orchard and our research partners are conducting clinical trials of investigational gene therapies for a number of rare, inherited diseases, including primary immune deficiencies, diseases of the brain and blood disorders. For more information about these trials, explore our pipeline or contact a member of Orchard medical information at firstname.lastname@example.org.